How has the product line changed from "sanitary material factory" to "Shiyao group"?

Johnson Most of the large pharmaceutical companies in China have experienced decades of development, which almost witnessed the changes in the demand of the drug market in China, with a strong sense of history From the health materials factory of Jizhong military region in 1938 to the establishment of the group in 1997, "Shiyao group" has now developed into one of the few large pharmaceutical companies in China And whether it is the traditional need of domestic imitation varieties, or a small number of class 1 new drugs on the market, the frequency of the emergence of Shiyao group is increasing, its development has touched the sensitive nerve of the domestic and even foreign pharmaceutical industry In 1938, Jizhong military region health material factory was the predecessor of Shiyao group, which mainly produced medical materials for war; in 1997, Shiyao group was established; in 2001, the enterprise implemented the enzyme 7-ACA expansion project, which filled in the domestic blank; in 2002, the national first-class new drug "butylphthalide" pilot production; in 2003, Shiyao group was listed in Hong Kong; in 2004, EBP (butylphthalide) was listed; in 2008, Wen In Sichuan earthquake, Sinopharm Group donated 12 million yuan of drugs and cash for the first time, and employees spontaneously donated 1.07 million yuan; in 2018, Sinopharm group became the first pharmaceutical stock in nearly 50 years since the establishment of Hang Seng Index According to the company's official website, the group has a total assets of 41 billion yuan and 25000 employees; Listed Companies in Hong Kong (01093 HK) are listed in the club with a market value of 100 billion yuan, which is a component of the Hang Seng Index and the first pharmaceutical stock in the 50 years since the establishment of the Hang Seng Index; on March 22, 2019, its subsidiary company, xinnuowei (300765 SZ), successfully listed on the gem, and the group realized "red chip + a" New era of financing pattern According to the mid-2019 report, as of June 30, 2019, the group's revenue was 11.178 billion yuan, an increase of 27.6% year-on-year; the drug business maintained an ideal growth in the first half of 2019, with sales revenue of 8.766 billion yuan, an increase of 36.8% year-on-year; the innovative drug products realized sales revenue of 6.149 billion yuan in the first half of 2019, an increase of 55.4% year-on-year, of which enbip increased by 35.9% and antineoplastic drug group A total increase of 194.2%, which is the two pillars of the group's performance growth Shiyao group has its own high-tech drug incubation base - Central Drug Research Institute of Shiyao group, with R & D centers and clinical centers in California, priston, Texas and New Jersey Shiyao group invests more than 10% of the sales revenue of finished drugs into product R & D and system construction, with an annual R & D investment of 2 billion yuan At present, it has established a research and development team of 1700 people, including thousands of highly educated talents such as master's degree and doctor's degree, and has established a complete research and development system in innovative drugs, generic drugs, biological drugs, antibody drugs, etc According to the interim report, the R & D cost invested in the first half of 2019 was 942 million RMB, an increase of 68.5% year on year, accounting for about 10.7% of the revenue of the patent medicine business At present, there are more than 300 research projects, including 40 small molecule new drugs and 30 new target macromolecule biological drugs, which are mainly concentrated in the fields of cardio cerebrovascular disease, anti-tumor, diabetes, mental and nervous diseases and anti infection Since 2000, the number of registration and application of varieties of Shiyao group has been close to 1000, which is declared by more than 10 subsidiaries; the year with the largest number of applications is 2011, which is more than 100, and now it has been more than 70 in 2019; in terms of registration and classification application types, the number of new varieties of Shiyao group is similar to that of imitated varieties, and a high proportion of innovative drugs are invested in large domestic pharmaceutical companies Relatively forward EBP is the third national class 1 new drug with independent intellectual property rights in China, which is used for the treatment of acute ischemic stroke It has entered into several stroke related treatment guidelines in China, and both dosage forms have been included in the national medical insurance catalog In foreign countries, the butylphthalide capsule has carried out phase II clinical treatment in the United States, and more than 100 patients have been enrolled Xuanning is mainly used for the treatment of hypertension, chronic stable angina and variant angina; Xuanning has successfully submitted a new drug listing application to the US FDA, which is the first time for Chinese pharmaceutical enterprises to submit a new drug listing application to the US FDA The group is transforming the sales mode of Xuanning into self-supporting mode, and strengthening the development of grass-roots and drugstore markets below the county level, so as to strive for greater market share and improve sales growth Jinyouli is the first long-term whitening drug independently developed in China, which can reduce the chance of infection of patients undergoing chemotherapy due to the low number of white blood cells and ensure the implementation of the standard chemotherapy dose The product has won the gold medal of China Patent and is seeking the opportunity of combination of immunotherapy and targeted therapy The new generation of paclitaxel chemotherapeutics, the first in China to imitate the market, successfully passed the consistency evaluation after the market, and won the "most innovative preparation variety in China" in 2018; in terms of price, Creole is far lower than the imported original research drug, greatly reducing the economic burden of patients At present, it is used in the treatment of breast cancer, and is expanding its application in lung cancer, pancreatic cancer, gastric cancer, melanoma, urothelial cancer, head and neck NPC, esophageal cancer and other fields Nolinine is mainly used in the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphocytic leukemia, but also in the treatment of gastrointestinal stromal tumor; the drug indications of patients must be used for a long time, the market potential is huge, the consistency evaluation work is advancing In addition to the above varieties, the company's products with high sales growth include aspirin enteric coated tablets, Mecobalamin tablets, metformin hydrochloride, etc.; meropenem in antibiotic products still maintains a rapid growth; there are 9 varieties of general medicine that have passed the consistency evaluation, namely azithromycin, tramadol tablets, captopril tablets, metformin hydrochloride tablets, Amoxicillin Capsules, ranitidine gum, etc Capsule, cefadroxil tablets, clopidogrel tablets, and tegrilol tablets Through data query, the current innovative drug pipeline of Shiyao group has been layered In addition to the class 1 new drugs that have been listed, there are varieties in research at all clinical stages Its targets, such as glp1r, CD20, EGFR, VEGFR, RANKL, HER2, IFNAR, are all hot targets, but they have not been involved in the current extremely hot PD-1 / PD-L1, etc.; in terms of indications, they are involved in cancer, cardiovascular, metabolism Etc.; see the table below for relevant variety information Reference resources: 1 Interim report 2019 of Shiyao Group Co., Ltd